Jeff Anderson |
For the first time, the HEOR team will be exhibiting at ISPOR EU 2022 in Vienna. With our passion for science and partnerships, our multi-disciplinary team will be on hand to answer your queries and help you navigate complex and ever-evolving requirements to achieve reimbursement and market access success.
When your collective challenge is to identify, generate, analyse and communicate evidence that is able to demonstrate the value of your product or intervention in competitive markets, you need help from a partner that’s more than just HEOR. A partner that can deploy world leading experts, can build long term strategic partnerships easily and quickly, can see the bigger value picture. At HEOR Ltd we think differently to generate better insights, make more impact and, importantly, we connect the dots so you don’t have to.
See our 10 poster presentations
Monday 7th November 10:00-13:15
Economic evaluation of patiromer for the treatment of hyperkalaemia in CKD patients with and without HF in Italy
An Economic Evaluation of Introducing Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients With Heart Failure From the Perspective of Healthcare Payers in Sweden, Germany, France, Poland and Spain
Mixture-cure Modelling of Overall Survival of Patients with Metastatic Non-small Cell Lung Cancer Receiving Nivolumab + Ipilimumab in CheckMate 277 – Updated with 5 years of Follow-Up
Tuesday 8th November 10:00-13:15
Challenges in Economic Modelling of Adjuvant Cancer Therapy for Health Technology Assessments
Humanistic and Economic Burden of Advanced Hepatocellular Carcinoma: A Systematic Review
Alleviating the Burden of Iron Deficiency in Heart Failure: A Multinational European Study
Impact of Model Approach on Economic Evaluation of Nivolumab Plus Chemotherapy for Advanced Gastric, Gastro-Oesophageal Junction and Oesophageal Cancer
Tuesday 8th November 15:00-18:15
Cost-Effectiveness Analysis of Introducing Ceftazidime-Avibactam to Treatment Strategies for Hospital-Acquired Infections in Greece
Health economic evaluation incorporating mixture cure survival analysis of nivolumab plus ipilimumab for previously untreated metastatic NSCLC
Use of Generalized F Parameterization in Long-Term Extrapolation for Adjuvant Cancer Therapies
Let us facilitate a time for a meeting, or simply let us know what day and time you will drop by our booth (X2-106 conveniently located next to the poster area). You can contact us at firstname.lastname@example.org
We’d love to hear your story in Vienna and we can tell you about ours!